Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance

被引：16
|
作者：
Kim, Hyungjoo [1 ,2 ]
Choi, Je-Min [1 ,3 ,4 ,5 ]
Lee, Kyung-min [1 ,3 ,4 ,5 ]
机构：
[1] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 04763, South Korea
[2] Penta Medix Co Ltd, Seongnam Si 13449, South Korea
[3] Hanyang Univ, Res Inst Nat Sci, Seoul 04763, South Korea
[4] Hanyang Univ, Res Inst Convergence Basic Sci, Seoul 04763, South Korea
[5] Hanyang Univ, Hanyang Inst Biosci & Biotechnol, Seoul 04763, South Korea
来源：
BIOMEDICINES | 2022年 / 10卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
immune checkpoint blockade; TNBC; resistance; IMMUNOHISTOCHEMISTRY IHC ASSAYS; PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; T-CELL IMMUNOTHERAPY; INDOLEAMINE 2,3-DIOXYGENASE; DOUBLE-BLIND; OPEN-LABEL; PD-L1; EXPRESSION; CRYOABLATION;
D O I：
10.3390/biomedicines10051130
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Mechanisms of immune evasion in triple-negative breast cancer patients.
    Orozco, Javier Ignacio
    Manughian-Peter, Ayla O.
    Salomon, Matthew P.
    O'Day, Steven
    Hoon, Dave S. B.
    Marzese, Diego M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Indian triple-negative breast cancer - immune, molecular and clinical landscape
    Sadanandam, A.
    Korlimarla, A.
    Ragulan, C.
    Prabhu, J.
    Shankaranarayana, H.
    Cheang, M.
    Sridhar, T. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression
    Seager, R. J.
    Pabla, Sarabjot
    Gandhi, Shipra
    Senosain, Maria-Fernanda
    Parikh, Hardik
    Van Roey, Erik
    Gao, Shuang
    Pulivendula, Yamuna
    DePietro, Paul
    Nesline, Mary K.
    Dash, Durga P.
    Conroy, Jeffrey M.
    Hastings, Stephanie B.
    Strickland, Kyle C.
    Previs, Rebecca A.
    Severson, Eric A.
    Caveney, Brian
    Jensen, Taylor J.
    Ramkissoon, Shakti H.
    Ko, Heidi Chwan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
    Gregorio, Ana C.
    Lacerda, Manuela
    Figueiredo, Paulo
    Simoes, Sergio
    Dias, Sergio
    Moreira, Joao Nuno
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) : 701 - 716
  • [25] Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
    Zhang, Zhiying
    Zhang, Rui
    Li, Donghai
    BIOLOGICS-TARGETS & THERAPY, 2023, 17 : 113 - 128
  • [26] Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
    Camorani, Simona
    Passariello, Margherita
    Agnello, Lisa
    Esposito, Silvia
    Collina, Francesca
    Cantile, Monica
    Di Bonito, Maurizio
    Ulasov, Ilya V.
    Fedele, Monica
    Zannetti, Antonella
    De Lorenzo, Claudia
    Cerchia, Laura
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [27] Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer
    Shen, Qiang
    Murakami, Kiichi
    Sotov, Valentin
    Butler, Marcus
    Ohashi, Pamela S.
    Reedijk, Michael
    SCIENCE ADVANCES, 2024, 10 (44):
  • [28] Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
    Said, Sawsan Sudqi
    Ibrahim, Wisam Nabeel
    BIOMEDICINES, 2024, 12 (02)
  • [29] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    D'Abreo, Nina
    Adams, Sylvia
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (07) : 399 - 400
  • [30] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    Nina D’Abreo
    Sylvia Adams
    Nature Reviews Clinical Oncology, 2019, 16 : 399 - 400
12345